The Spectrum of Molecular Pathways in Gliomas-An Up-to-Date Review

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Aug 26

PMID 37626776

Authors

Reinhold Nafe

Elke Hattingen

Affiliations

Soon will be listed here.

Abstract

During the last 20 years, molecular alterations have gained increasing significance in the diagnosis and biological assessment of tumors. Gliomas represent the largest group of tumors of the central nervous system, and the main aim of this review is to present the current knowledge on molecular pathways and their alterations in gliomas. A wide range of new insights has been gained, including evidence for the involvement of the WNT pathway or the hippo pathway in the pathobiology of gliomas, indicating a broad involvement of different pathways formerly not considered to play a central role in gliomas. Even new aspects of angiogenic, apoptotic, and metabolic pathways are presented, as well as the rapidly growing field of epigenetic processes, including non-coding RNAs. The two major conclusions drawn from the present review are the distinct interconnectivity of the whole spectrum of molecular pathways and the prominent role of non-coding RNAs, especially circular RNAs, in the regulation of specific targets. All these new insights are discussed, even considering the topic of the resistance to therapy of gliomas, along with aspects that are still incompletely understood, like the role of hydroxymethylation, or even ferroptosis, in the pathobiology of gliomas.

Citing Articles

The role of lncRNAs in the interplay of signaling pathways and epigenetic mechanisms in glioma.

Bora Yildiz C, Du J, Mohan K, Zimmer-Bensch G, Abdolahi S Epigenomics. 2025; 17(2):125-140.

PMID: 39829063 PMC: 11792803. DOI: 10.1080/17501911.2024.2442297.

Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers.

Varachev V, Susova O, Mitrofanov A, Naskhletashvili D, Krasnov G, Ikonnikova A Int J Mol Sci. 2024; 25(23).

PMID: 39684714 PMC: 11641329. DOI: 10.3390/ijms252313004.

Emerging Role of the Slit/Roundabout (Robo) Signaling Pathway in Glioma Pathogenesis and Potential Therapeutic Options.

Markouli M, Papachristou A, Politis A, Boviatsis E, Piperi C Biomolecules. 2024; 14(10).

PMID: 39456164 PMC: 11506736. DOI: 10.3390/biom14101231.

Protein Fold Usages in Ribosomes: Another Glance to the Past.

Tanoz I, Timsit Y Int J Mol Sci. 2024; 25(16).

PMID: 39201491 PMC: 11354259. DOI: 10.3390/ijms25168806.

Multiple Administration of Dexamethasone Possesses a Deferred Long-Term Effect to Glycosylated Components of Mouse Brain.

Aladev S, Sokolov D, Strokotova A, Kazanskaya G, Volkov A, Aidagulova S Neurol Int. 2024; 16(4):790-803.

PMID: 39051219 PMC: 11270268. DOI: 10.3390/neurolint16040058.

References

Chou F, Liu Y, Lang F, Yang C . D-2-Hydroxyglutarate in Glioma Biology. Cells. 2021; 10(9). PMC: 8464856. DOI: 10.3390/cells10092345. View

Zhu Z, Zhai Y, Hao Y, Wang Q, Han F, Zheng W . Specific anti-glioma targeted-delivery strategy of engineered small extracellular vesicles dual-functionalised by Angiopep-2 and TAT peptides. J Extracell Vesicles. 2022; 11(8):e12255. PMC: 9451528. DOI: 10.1002/jev2.12255. View

Guo Q, Guo J, Liu W, Hu S, Hu X, Wang Q . Circ-EGFR Functions as an Inhibitory Factor in the Malignant Progression of Glioma by Regulating the miR-183-5p/TUSC2 Axis. Cell Mol Neurobiol. 2021; 42(7):2245-2256. PMC: 11421611. DOI: 10.1007/s10571-021-01099-y. View

Di Fiore R, DAnneo A, Tesoriere G, Vento R . RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol. 2013; 228(8):1676-87. DOI: 10.1002/jcp.24329. View

Babic I, Anderson E, Tanaka K, Guo D, Masui K, Li B . EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013; 17(6):1000-1008. PMC: 3679227. DOI: 10.1016/j.cmet.2013.04.013. View

Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010; 12(11):1102-12. PMC: 3098027. DOI: 10.1093/neuonc/noq080. View

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

Zheng K, Xie H, Wu W, Wen X, Zeng Z, Shi Y . CircRNA PIP5K1A promotes the progression of glioma through upregulation of the TCF12/PI3K/AKT pathway by sponging miR-515-5p. Cancer Cell Int. 2021; 21(1):27. PMC: 7789671. DOI: 10.1186/s12935-020-01699-6. View

Delen E, Doganlar O . The Dose Dependent Effects of Ruxolitinib on the Invasion and Tumorigenesis in Gliomas Cells via Inhibition of Interferon Gamma-Depended JAK/STAT Signaling Pathway. J Korean Neurosurg Soc. 2020; 63(4):444-454. PMC: 7365278. DOI: 10.3340/jkns.2019.0252. View

10.

Chow M, Luster A . Chemokines in cancer. Cancer Immunol Res. 2014; 2(12):1125-31. PMC: 4258879. DOI: 10.1158/2326-6066.CIR-14-0160. View

11.

Afonso M, Brito M . Therapeutic Options in Neuro-Oncology. Int J Mol Sci. 2022; 23(10). PMC: 9140894. DOI: 10.3390/ijms23105351. View

12.

Amankulor N, Kim Y, Arora S, Kargl J, Szulzewsky F, Hanke M . Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017; 31(8):774-786. PMC: 5435890. DOI: 10.1101/gad.294991.116. View

13.

Xu X, Lai Y, Hua Z . Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2018; 39(1). PMC: 6340950. DOI: 10.1042/BSR20180992. View

14.

Dabrowski M, Wojtas B . Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications. Int J Mol Sci. 2019; 20(14). PMC: 6678179. DOI: 10.3390/ijms20143478. View

15.

Peng D, Luo L, Zhang X, Wei C, Zhang Z, Han L . CircRNA: An emerging star in the progression of glioma. Biomed Pharmacother. 2022; 151:113150. DOI: 10.1016/j.biopha.2022.113150. View

16.

Guo X, Sui R, Piao H . Tumor-derived small extracellular vesicles: potential roles and mechanism in glioma. J Nanobiotechnology. 2022; 20(1):383. PMC: 9400220. DOI: 10.1186/s12951-022-01584-6. View

17.

Ohba S, Mukherjee J, Johannessen T, Mancini A, Chow T, Wood M . Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016; 76(22):6680-6689. PMC: 5290072. DOI: 10.1158/0008-5472.CAN-16-0696. View

18.

Ozair A, Bhat V, Alisch R, Khosla A, Kotecha R, Odia Y . DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. Cancers (Basel). 2023; 15(4). PMC: 9954183. DOI: 10.3390/cancers15041342. View

19.

de Souza C, Sabedot T, Malta T, Stetson L, Morozova O, Sokolov A . A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Rep. 2018; 23(2):637-651. PMC: 8859991. DOI: 10.1016/j.celrep.2018.03.107. View

20.

Lv D, Jia F, Hou Y, Sang Y, Alvarez A, Zhang W . Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding. Cancer Res. 2017; 77(22):6190-6201. PMC: 5690809. DOI: 10.1158/0008-5472.CAN-17-1388. View